316 related articles for article (PubMed ID: 16005252)
1. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.
Clemmons DR; Moses AC; Sommer A; Jacobson W; Rogol AD; Sleevi MR; Allan G
Growth Horm IGF Res; 2005 Aug; 15(4):265-74. PubMed ID: 16005252
[TBL] [Abstract][Full Text] [Related]
2. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
Clemmons DR; Sleevi M; Allan G; Sommer A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.
Saukkonen T; Shojaee-Moradie F; Williams RM; Amin R; Yuen KC; Watts A; Acerini CL; Umpleby AM; Dunger DB
Diabetes; 2006 Aug; 55(8):2365-70. PubMed ID: 16873702
[TBL] [Abstract][Full Text] [Related]
4. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
[TBL] [Abstract][Full Text] [Related]
6. [Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes].
Kato M
Hokkaido Igaku Zasshi; 1998 Nov; 73(6):613-25. PubMed ID: 10036618
[TBL] [Abstract][Full Text] [Related]
7. The effects of recombinant human insulin-like growth factor (rhIGF)-1 and rhIGF-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy.
Narusawa K; Nakamura T; Suzuki K; Matsuoka Y; Lee LJ; Tanaka H; Seino Y
J Bone Miner Res; 1995 Dec; 10(12):1853-64. PubMed ID: 8619365
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.
Zenobi PD; Jaeggi-Groisman SE; Riesen WF; Røder ME; Froesch ER
J Clin Invest; 1992 Dec; 90(6):2234-41. PubMed ID: 1469083
[TBL] [Abstract][Full Text] [Related]
9. The effects of infusion of insulinlike growth factor (IGF) I, IGF-II, and insulin on glucose and protein metabolism in fasted lambs.
Douglas RG; Gluckman PD; Ball K; Breier B; Shaw JH
J Clin Invest; 1991 Aug; 88(2):614-22. PubMed ID: 1864971
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3): effects on the glycemic and growth promoting activities of rhIGF-1 in the rat.
Clark RG; Mortensen D; Reifsynder D; Mohler M; Etcheverry T; Mukku V
Growth Regul; 1993 Mar; 3(1):50-2. PubMed ID: 7683530
[TBL] [Abstract][Full Text] [Related]
11. Provision of rhIGF-I/IGFBP-3 complex attenuated development of cancer cachexia in an experimental tumor model.
Wang W; Iresjö BM; Karlsson L; Svanberg E
Clin Nutr; 2000 Apr; 19(2):127-32. PubMed ID: 10867731
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
[TBL] [Abstract][Full Text] [Related]
14. Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens.
Yagasaki H; Kobayashi K; Saitou T; Nagamine K; Mitsui Y; Mochizuki M; Kobayashi K; Cho H; Ohyama K; Amemiya S; Nakazawa S
Exp Clin Endocrinol Diabetes; 2010 Mar; 118(3):195-9. PubMed ID: 19834874
[TBL] [Abstract][Full Text] [Related]
15. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
[TBL] [Abstract][Full Text] [Related]
16. Continuous longitudinal infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants: Evaluation of feasibility in a phase II study.
Hansen-Pupp I; Hellström A; Hamdani M; Tocoian A; Kreher NC; Ley D; Hallberg B
Growth Horm IGF Res; 2017 Oct; 36():44-51. PubMed ID: 28934640
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats.
Cox GN; McDermott MJ; Merkel E; Stroh CA; Ko SC; Squires CH; Gleason TM; Russell D
Endocrinology; 1994 Nov; 135(5):1913-20. PubMed ID: 7525258
[TBL] [Abstract][Full Text] [Related]
18. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
[TBL] [Abstract][Full Text] [Related]
19. Repeated sc administration of recombinant human insulin-like growth factor I (IGF-I) to human subjects for 7 days.
Takano K; Hizuka N; Shizume K; Asakawa K; Fukuda I; Demura H
Growth Regul; 1991 Mar; 1(1):23-8. PubMed ID: 1842557
[TBL] [Abstract][Full Text] [Related]
20. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
